Idiopathic Pulmonary Fibrosis (IPF) Emerging Therapy and TPP Insights

Thelansis’s “Idiopathic Pulmonary Fibrosis (IPF) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2026″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Idiopathic Pulmonary Fibrosis (IPF) Overview

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and ultimately fatal fibrosing interstitial lung disease of unknown aetiology, characterised by aberrant epithelial injury responses, fibroblast activation, and excessive extracellular matrix deposition — producing the pathological hallmark of usual interstitial pneumonia (UIP) — resulting in irreversible destruction of lung architecture and progressive respiratory failure. Genetic susceptibility variants, particularly MUC5B promoter polymorphisms, alongside ageing, cigarette smoking, gastro-oesophageal reflux, and occupational dust exposures are recognised risk determinants. Patients — predominantly older males — present insidiously with progressive exertional dyspnoea, dry cough, and bibasal inspiratory velcro-like crackles, with clubbing present in a significant proportion. Diagnosis integrates high-resolution CT demonstrating characteristic UIP pattern — subpleural, basal-predominant honeycombing with or without traction bronchiectasis — alongside pulmonary function testing revealing restrictive physiology and reduced DLCO; surgical lung biopsy is reserved for diagnostically uncertain cases. Antifibrotic therapies — nintedanib and pirfenidone — slow FVC decline and disease progression but do not reverse established fibrosis. Lung transplantation remains the only potentially life-extending intervention in eligible patients. Pulmonary rehabilitation, supplemental oxygen, and proactive management of comorbidities — including pulmonary hypertension and acute exacerbations — are essential. Prognosis remains poor with median survival of two to five years; early palliative integration, advance care planning, and compassionate patient-centred support are indispensable throughout the disease trajectory.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)